<table id="table_4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4.  Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)</caption>
<colgroup>
<col></col>
<col></col>
</colgroup>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Botrule Rrule" valign="middle">Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased SYNTHROID requirements.</td>
</tr>
<tr valign="top">
<td align="center" stylecode="Toprule Botrule Rrule">
<content stylecode="bold">Drug or Drug Class</content>
</td>
<td align="center" stylecode="Toprule Botrule Rrule">
<content stylecode="bold">Effect</content>
</td>
</tr>
<tr valign="top">
<td align="left" stylecode="Toprule Botrule Rrule">Phenobarbital<br/>Rifampin</td>
<td align="left" stylecode="Toprule Botrule Rrule">Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5â€™-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.</td>
</tr>
</tbody>
</table>